|
Combat the COVID-19 |
Let's Combat COVID-19 Pandemic Together
The COVID-19 outbreak presents the unprecedented challenge for world public and medical practitioners and health care providers. The Elmer Press Inc is herein to participate the combating COVID-19 through all possible efforts, as a clinical medicine publisher, we would facilitate the rapid and effective communication of management of this pandemic, we will consider submissions related to all aspects of this disease, including prevention, basic viral research, epidemiology, treatment, vaccine, fast screening, diagnosis, prognosis, etc. We will process such manuscripts in priority and publish them ASAP after peer-reviewed and accepted.
Highlights |
-
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic LeukemiaWe conducted a phase 2 trial involving patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients were treated with ofatumumab with fresh frozen plasma (FFP) used as a source of complement replacement.
Read More >> -
Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual DiseaseAlthough rare, spontaneous remission (SR) of acute myeloid leukemia (AML) has been reported in the literature, the underlying mechanisms driving remission remain unknown. However, it is most commonly associated with a preceding severe infection.
Read More >> -
Impact of Opioid Use in Hematological Malignancies: Clinical, Immunological and Concomitant AspectsOpioid agents play a unique role in pain and symptom management for cancer patients. Research shows that opiate use, especially when associated with underlying cancer, has significant effects on hematological parameters.
Read More >> -
Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot StudyIbrutinib is a Bruton’s tyrosine kinase inhibitor that has shown to be a superior choice in the treatment of chronic lymphocytic leukemia (CLL) and a simple, oral alternative to other chemoimmunotherapies.
Read More >> -
Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With CaplacizumabCaplacizumab has emerged as a promising new drug for the management of TTP. We report the case of a patient with idiopathic refractory TTP treated with caplacizumab who developed thrombotic complications upon discontinuation of treatment.
Read More >>
Viewpoints |
|
| Featured |
|
| Management of Iron-Deficiency Anemia on Inpatients and Appropriate Discharge and Follow-Up | |||
Image of the Issue |
Novel Translocation in Acute Myeloid Leukemia: Case Report and Review of Risk-Stratification and Induction Chemotherapy in Patients With Acute Myeloid Leukemia
Identification of chromosomal abnormalities in patients with acute myeloid leukemia (AML) has contributed substantially to our current understanding of the molecular pathogenesis underlying leukemogenesis, and risk-stratification based on molecular abnormalities both influences treatment strategies and aids in determining prognosis. Full Text
Current Issue |
Past IssuesVol. 9, No. 3, Sept 2020
Table of Contents
Review
| Impact of Opioid Use in Hematological Malignancies: Clinical, Immunological and Concomitant Aspects | Abstract HTML PDF |
| Polina Tregubenko, Valeriy Zvonarev | 41-54 |
| doi: https://doi.org/10.14740/jh689 |
Original Article
| Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study | Abstract HTML PDF |
| William Alexander, Sarah Davis, Raj Ramakrishna, Arumugam Manoharan | 55-61 |
| doi: https://doi.org/10.14740/jh676 |
| Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia | Abstract HTML PDF |
| Esraa Jamal, Emad Azmy, Mohamed Ayed, Salah Aref, Noha Eisa | 62-70 |
| doi: https://doi.org/10.14740/jh655 |
Short Communication
| Clinical Features of Plasmablastic Lymphoma: Case Series From an Asian Tertiary Cancer Center and Literature Review | Abstract HTML PDF Suppl1 |
| Daniel Ren Yi Yap, Grace Fangmin Tan, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamad Farid, Tiffany Tang, Miriam Tao, Soon Thye Lim, Jason Yongsheng Chan | 71-78 |
| doi: https://doi.org/10.14740/jh672 |
| Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia | Abstract HTML PDF Suppl1 |
| Joseph Tuscano, Christina Poh, Aaron Rosenberg, Brian Jonas, Mehrdad Abedi, Gustavo Barisone, Emily Schwab, Kathleen Lundeberg, Paul Kaesberg | 79-83 |
| doi: https://doi.org/10.14740/jh721 |
Case Report
| Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab | Abstract HTML PDF |
| Nicolas Cilla, Julie Dallemagne, Marie Vanhove, Patrick Stordeur, Serge Motte, Virginie De Wilde | 84-88 |
| doi: https://doi.org/10.14740/jh614 |
| Severe Peripheral Neuropathy From Treatment With Arsenic Trioxide in a Patient Suffering From Acute Promyelocytic Leukemia | Abstract HTML PDF |
| Soren Niemi Helso, Anne Stidsholt Roug, Morten Mork, Eva Futtrup Maksten, Marianne Tang Severinsen | 89-92 |
| doi: https://doi.org/10.14740/jh617 |
Letter to the Editor
| Prevalence of Sickle Cell Trait and Rare Hemoglobin Variants in the Metropolitan Washington DC Area | Abstract HTML PDF Suppl1 Suppl2 |
| Xiaomei Niu, Christian S. Parry, Angela Mason, Barbara Harrison, Seyed Mehdi Nouraie, Tatiana Ammosova, Juan Salomon-Andonie, Patricia A. Oneal, Victor R. Gordeuk, James G. Taylor, Sergei Nekhai | 93-95 |
| doi: https://doi.org/10.14740/jh603 |